Brief: Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For Treatment Of Covid-19
29/07/2022 12:33
July 29 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL STUDY
ASSESSING TEMPOL FOR THE TREATMENT OF COVID-19
* ADAMIS PHARMACEUTICALS CORP - NEXT DATA SAFETY MONITORING
BOARD
(DSMB) MEETING TO REVIEW INTERIM DATA RESULTS HAS BEEN SCHEDULED
FOR LATE SEPTEMBER
* ADAMIS PHARMACEUTICALS - AT SEPT MEETING, DSMB PLANS TO
EVALUATE
PRIMARY EFFICACY ENDPOINT, SUSTAINED RESOLUTION OF COVID-19
SYMPTOMS, OTHER ASPECTS
Source text for Eikon: ID:nGNX82Ghqy
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update